Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, ...
What is the expected timeline for potential commercialization or partnership revenue from NGN-401, and what milestones would trigger upside price movement?
What are the key risks highlighted in the earnings release (e.g., trial outcomes, regulatory delays, competition) and how might they affect the company's risk profile?
How does the progress of NGN-401 compare to competitor pipelines targeting Rett syndrome or related neurodevelopmental disorders?
13 days ago